Arcus Biosciences Inc (NYSE: RCUS) on Friday, soared 3.15% from the previous trading day, before settling in for the closing price of $12.70. Within the past 52 weeks, RCUS’s price has moved between $11.55 and $20.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 186.11% over the past five years. The company achieved an average annual earnings per share of 17.81%. With a float of $48.82 million, this company’s outstanding shares have now reached $91.50 million.
Let’s look at the performance matrix of the company that is accounted for 577 employees. In terms of profitability, gross margin is 96.2%, operating margin of -120.91%, and the pretax margin is -102.28%.
Arcus Biosciences Inc (RCUS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcus Biosciences Inc is 46.55%, while institutional ownership is 55.14%. The most recent insider transaction that took place on Dec 31 ’24, was worth 53,910. In this transaction Chief Financial Officer of this company sold 3,594 shares at a rate of $15.00, taking the stock ownership to the 60,138 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Officer proposed sale 3,594 for $15.00, making the entire transaction worth $53,910.
Arcus Biosciences Inc (RCUS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.91% during the next five years compared to -23.70% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Arcus Biosciences Inc (RCUS) is currently performing well based on its current performance indicators. A quick ratio of 5.23 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -4.33 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Arcus Biosciences Inc (NYSE: RCUS) saw its 5-day average volume 0.49 million, a negative change from its year-to-date volume of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 46.67%. Additionally, its Average True Range was 0.65.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 20.86%, which indicates a significant decrease from 68.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.80% in the past 14 days, which was lower than the 52.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.66, while its 200-day Moving Average is $15.69. Nevertheless, the first resistance level for the watch stands at $13.48 in the near term. At $13.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.24. If the price goes on to break the first support level at $12.72, it is likely to go to the next support level at $12.35. The third support level lies at $11.96 if the price breaches the second support level.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
Market capitalization of the company is 1.20 billion based on 91,512K outstanding shares. Right now, sales total 117,000 K and income totals -307,000 K. The company made 48,000 K in profit during its latest quarter, and -92,000 K in sales during its previous quarter.
